Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costs

Reuters2025-11-08

Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costs

Overview

Surrozen Q3 net loss widens significantly year-over-year, with no collaboration revenue
Operating expenses increased due to higher R&D costs in ophthalmology programs
Company strengthens leadership with new CFO, Andrew Maleki, focusing on growth

Outlook

Company did not provide specific financial guidance for the current or future periods

Result Drivers

INCREASED R&D EXPENSES - R&D expenses rose due to higher manufacturing costs, lab expenses, and consulting fees for ophthalmology programs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$8.36
Q3 Net Income		-$71.64 mln
Q3 Operating Expenses		$11.87 mln
Q3 Operating Income		-$10.89 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Surrozen Inc is $37.00, about 66.2% above its November 6 closing price of $12.50

Press Release: ID:nGNX6RnHJ9

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581315868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581315868","market":"nz","top_or_hot":-1,"title":"Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotechnology firm Surrozen's Q3 net loss widens on higher R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>Surrozen Q3 net loss widens significantly year-over-year, with no collaboration revenue</p></li><li><p>Operating expenses increased due to higher R&amp;D costs in ophthalmology programs</p></li><li><p>Company strengthens leadership with new CFO, Andrew Maleki, focusing on growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for the current or future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - R&amp;D expenses rose due to higher manufacturing costs, lab expenses, and consulting fees for ophthalmology programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$8.36</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$71.64 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$11.87 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$10.89 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Surrozen Inc is $37.00, about 66.2% above its November 6 closing price of $12.50</p></li></ul><p>Press Release: <span>ID:nGNX6RnHJ9</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotechnology firm Surrozen's Q3 net loss widens on higher R&D costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-08 05:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotechnology firm Surrozen's Q3 net loss widens on higher R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>Surrozen Q3 net loss widens significantly year-over-year, with no collaboration revenue</p></li><li><p>Operating expenses increased due to higher R&amp;D costs in ophthalmology programs</p></li><li><p>Company strengthens leadership with new CFO, Andrew Maleki, focusing on growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for the current or future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - R&amp;D expenses rose due to higher manufacturing costs, lab expenses, and consulting fees for ophthalmology programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$8.36</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$71.64 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$11.87 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$10.89 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Surrozen Inc is $37.00, about 66.2% above its November 6 closing price of $12.50</p></li></ul><p>Press Release: <span>ID:nGNX6RnHJ9</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRZN","symbol_name":"Surrozen, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ16K:1","article_id":"2581315868","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581315868","pubTimestamp":1762550067,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costsOverviewSurrozen Q3 net loss widens significantly year-over-year, with no collaboration revenueOperating expenses increased due to h","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRZN":"Surrozen, Inc.","BK4139":"生物科技"},"translate_title":"生物技术公司Surrozen第三季度净亏损因研发成本上升而扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRZN":0.9},"content_text":"Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costsOverviewSurrozen Q3 net loss widens significantly year-over-year, with no collaboration revenueOperating expenses increased due to higher R&D costs in ophthalmology programsCompany strengthens leadership with new CFO, Andrew Maleki, focusing on growthOutlookCompany did not provide specific financial guidance for the current or future periodsResult DriversINCREASED R&D EXPENSES - R&D expenses rose due to higher manufacturing costs, lab expenses, and consulting fees for ophthalmology programsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$8.36Q3 Net Income-$71.64 mlnQ3 Operating Expenses$11.87 mlnQ3 Operating Income-$10.89 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Surrozen Inc is $37.00, about 66.2% above its November 6 closing price of $12.50Press Release: ID:nGNX6RnHJ9For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581315868","isCrawlerRequest":true}